A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

By R. Garrick. 2010

1,024 citations recorded by the source corpus.

Subfields: Hematology, Nephrology

View Paper: https://www.semanticscholar.org/paper/77432b35b2c9634f6efb85a0cdb426f3bf22ae48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nephrology

1. A. Levey
2. Josef Coresh
3. Marcello Tonelli
4. Harold I. Feldman
5. A. Levin
6. R. Gansevoort
7. Giuseppe Remuzzi
8. R. Mehta

Citations in the corpus

• Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. (2017, background): “, ALTIDUDE,(222) BEACON,(223) ASCEND,(224) VANEPHRON D,(225) and TREAT.(226) The reasons for this may relate to the endpoint chosen, or to aspects of study design or conduct.”
• Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, background): “Erythropoiesis-stimulating agents and/ or intravenous iron(107) may improve exercise tolerance but are without survival benefit.(108,109) Control of calcium and phosphate concentrations is instrumental in minimizing vessel calcification.”